ライフサイエンスコーパス: binding potential

1 r molecular docking to assess protein-ligand binding potential.

2 ith changes in regional SERT nondisplaceable binding potential.

3 ant (25.8 +/- 7.8%) reduction in [(11)C]DTBZ binding potential.

4 C]P943, for purposes of quantifying regional binding potential.

5 MPBind achieved high prediction accuracy for binding potential.

6 inding but the propagation to reach its full binding potential.

7 during mitosis by reducing its intrinsic DNA binding potential.

8 reference tissue methods regarding regional binding potential.

9 changes in [(11)C]raclopride nondisplaceable binding potential.

10 nthesis capacity showed higher D2/3 receptor-binding potential.

11 generate parametric maps of 11C-(R)-PK11195 binding potential.

12 (efflux rate), with no significant impact on binding potential.

13 ative to the cerebellar gray matter (R1) and binding potentials.

14 selected as a reference region to calculate binding potentials.

15 tatively accurate method for estimating SERT binding potentials.

16 ration was sufficient to quantify VT and the binding potentials.

17 Binding potential (a measure of amyloid burden) was calc

18 l connectivity also correlated with baseline binding potential across cortical and extrastriatal subc

19 sporter availability (measured by changes in binding potential) after modafinil when compared with af

20 Ligand binding potentials against individual proteins can be di

21 apillomavirus (HPV) E6 oncoproteins have PDZ binding potential, an activity which is important for th

22 ndent bias in the estimate of tissue-derived binding potential and care must be taken in comparing (1

23 ttern and extrastriatal baseline D2 receptor binding potential and its change after amphetamine admin

24 ns to the linker are designed to improve the binding potential and pharmacokinetics for theranostic a

25 agonist of alpha4beta2-nAChRs, that has high binding potential and rapid brain kinetics in baboons.

26 discovered and shown to possess higher CXCR4 binding potential and specificity than 5.

27 rivation of regional distribution volume and binding potential and to determine the repeatability of

28 L1 proteins also exhibit a unique nucleotide-binding potential and, whereas the larger A and B isofor

29 t arginine 100, interfering with its RAS/RAF binding potential, and therefore altering extracellular

30 In vivo AML blasts with highest E-selectin binding potential are 12-fold more likely to survive che

31 del in which the effects of the shape of the binding potential are used to quantify the kinetic param

32 Binding potentials around 0.8-1.2 were estimated using d

33 otonin synthesis rate capacity and [11C]DASB binding potential as an index of serotonin transporter a

34 issue and enabled the estimation of regional binding potential as the outcome measure of specific bin

35 n levels of amyloid load and 11C-(R)-PK11195 binding potentials at a voxel level within subregions of

36 Binding potentials averaged 0.6-0.8 in the cortex and 0.

37 BPIT was supported as a method for regional binding potential, B(max), and K(D).

38 -alpha-induced changes in DA2 receptor (D2R) binding potential before and after intravenous amphetami

39 lease was estimated as the percent change in binding potential between conditions (stress and control

40 Understanding the binding potential between MHC and peptides can lead to t

41 The decrease in binding potential between the pre- and posttreatment sca

42 omparing the percentage change of raclopride binding potential between the two Parkinson's disease gr

43 inding of [(11)C]raclopride (nondisplaceable binding potential) between baseline values and values fo

44 ), and 3 binding potentials (nondisplaceable binding potential, binding potential relative to total p

45 binding, as measured by the nondisplaceable binding potential (BP (ND)) for the 3 tracers ((11)C-EKA

46 tribution volume (V (T)) and nondisplaceable binding potential (BP (ND)) in various brain regions.

47 re compared with model-based nondisplaceable binding potential (BP (ND)) to select the optimal time w

48 ompute total distribution volume (V (T)) and binding potential (BP (ND)).

49 When using binding potential (BP(F) = B(avail)/K(D) [total availabl

50 Nondisplaceable binding potential (BP(ND) ) for each ligand was quantifi

51 f the effects of OPRM1 A118G genotype on MOR binding potential (BP(ND) or receptor availability).

52 The frontal cortex binding potential (BP(ND)(frontal)) was calculated as (V

53 on between [(18)F]fallypride nondisplaceable binding potential (BP(ND)) and MPH dose in the head of t

54 SRTM binding potential (BP(ND)) and reference Logan DVR-1 val

55 lated gray matter atrophy on nondisplaceable binding potential (BP(ND)) as determined by a validated

56 of each PET measured the uOR nondisplaceable binding potential (BP(ND)) at resting state, and the las

57 The outcome measure was the binding potential (BP(ND)) estimated with the simplified

58 The primary outcome was binding potential (BP(ND)) in the anterior cingulate cor

59 ed from SUV ratio (SUVr) and nondisplaceable binding potential (BP(ND)) methods, with cerebellar gray

60 I volume (obtained with RC(zmin) = 50%), the binding potential (BP(ND)) of (11)C-raclopride was found

61 Main Outcome Measure Regional [(11)C]P943 binding potential (BP(ND)) values in an a priori-defined

62 ose at elevated risk had lower [(11)C]ABP688 binding potential (BP(ND)) values in the striatum, amygd

63 [11C]UCB-J binding potential (BP(ND)) was estimated using a one-tis

64 VMAT2 binding potential (BP(ND)) was estimated voxelwise by us

65 [(1)(1)C]DTBZ nondisplaceable binding potential (BP(ND)) was measured by kinetic analy

66 Binding potential (BP(ND)) was quantified before and aft

67 Regional estimates of binding potential (BP(ND)) were obtained by calculating

68 Binding potential (BP(ND)), an index of tracer-specific

69 c modeling was applied to calculate regional binding potential (BP(ND)), and 1- and 2-site binding cu

70 distribution volume (V(T)), nondisplaceable binding potential (BP(ND)), and receptor occupancy.

71 e nondisplaceable striatal D(2)/(3) receptor binding potential (BP(ND)).

72 microdialysis and decrease in [(11)C]FLB 457 binding potential (BP(ND), 0.3 mg kg(-1): -6+/-6%; 0.5 m

73 VAChT binding parameter, the nondisplaceable binding potential (BP(ND-MRTM2)).

74 crease (P = 0.0012) in mean hypothalamic RAC binding potential (BP) and a significant increase in mea

75 Thus, we correlated 5HT(2A) binding potential (BP) and RNA gene expression in 16 SLC

76 DA availability was assessed by measuring D1 binding potential (BP) during rest using PET.

77 We examined links between DA D(1) binding potential (BP) in multiple brain regions and IIV

78 ized that beer's flavor alone can reduce the binding potential (BP) of [(11)C]raclopride (RAC; a refl

79 lthy controls, had bilaterally decreased RAC binding potential (BP) to striatal dopamine D2/D3 recept

80 We correlated changes in [(123)I]IBZM binding potential (BP) with plasma levels of homovanilli

81 R availability, as measured by 18F-F-A-85380 binding potential (BP), using linear regression.

82 anges in the 5HT transporter and 2A receptor binding potential (BP).

83 The binding potential (BP; proportional to receptor concentr

84 ume corrected [(11) C]ABP688 nondisplaceable binding potentials (BP(ND) ) between groups using region

85 Voxel-wise binding potentials (BP(ND)) for SERT and DAT were determ

86 tal distribution volumes and nondisplaceable binding potentials (BP(ND)) were used to compare regiona

87 city (cm3), which is a summed voxel value of binding potentials (BP*ND) multiplied by voxel volume.

88 SERT and 5-HT(2A) receptor availability (binding potential, BP(ND)) were analyzed with a two-tiss

89 D(2)R availability (non-displaceable binding potential; BP(ND)) was measured pre- and post-am

90 imation in graphical analysis [LEGA]), using binding potential (BPF = Bmax/Kd) (Bmax = maximum number

91 free-fraction measurement to estimate 5-HT1A binding potential (BPF = Bmax/KD, where Bmax = available

92 The binding potential (BPF) of [11C]WAY-100635 (calculated a

93 h methods, all patients had clearly elevated binding potential (BPND (non-displaceable binding potent

94 For binding potential (BPND and BPP), the test-retest variab

95 s not related to a change in nondisplaceable binding potential (BPND) but rather to an increase in th

96 inding potential relative to nondisplaceable binding potential (BPND) by multilinear analysis, simpli

97 D2-type receptor availability, indicated by binding potential (BPND) for [(18)F]fallypride.

98 Parametric nondisplaceable binding potential (BPND) images were compared with stand

99 on, were applied to generate nondisplaceable binding potential (BPND) images.

100 The percentage change in binding potential (BPND) in the DLPFC following amphetam

101 OXT increased [(18)F]MPPF nondisplaceable binding potential (BPND) in the dorsal raphe nucleus (DR

102 10 healthy volunteers), the nondisplaceable binding potential (BPND) obtained from the full kinetic

103 The binding potential (BPND) of (11)C-PBR28 was significantl

104 Regional estimates of the binding potential (BPND) of [(11)C]IMA107 were generated

105 tions and comparing striatal nondisplaceable binding potential (BPND) using a simplified reference ti

106 g allowed calculation of the nondisplaceable binding potential (BPND) values for the binding of (123)

107 Mean striatal nondisplaceable binding potential (BPND) values were 2.0 after injection

108 Binding potential (BPND) values were computed as [(CROI/

109 rves were extracted, and the nondisplaceable binding potential (BPND) was calculated by use of the si

110 njection of the radiotracer, [(11)C]GR103545 binding potential (BPND) was decreased in a dose-depende

111 [(11)C]N-propyl-norapomorphine ([(11)C]NPA) binding potential (BPND) was measured in 14 off-medicati

112 [(11)C]FLB457-binding potential (BPND) was measured pre- and post amph

113 Parametric images of (18)F-FMZ binding potential (BPND) were generated using the simpli

114 Parametric maps of (11)C-(R)PK11195 binding potential (BPND) were generated.

115 tes of regional distribution volume (VT) and binding potential (BPND) with 120 min of scan data.

116 We hypothesized that (11)C-flumazenil binding potential (BPND) would be higher in isoflurane-a

117 or availability (measured as nondisplaceable binding potential (BPND)) in patients with Parkinson's d

118 ne D2-type receptor availability, indexed by binding potential (BPND), and functional magnetic resona

119 methods to estimate the distribution volume, binding potential (BPND), and SUVR.

120 plified models were also tested to calculate binding potential (BPND), including the simplified refer

121 reference tissue models for nondisplaceable binding potential (BPND), supporting noninvasive quantif

122 The outcome measure was the binding potential (BPND), using the cerebellum as the re

123 ) has been used to determine nondisplaceable binding potential (BPND), which is defined as the quotie

124 DA release was measured as change in binding potential (BPND).

125 e of distribution (VND), and nondisplaceable binding potential (BPND); and dosimetry.

126 ormal reductions in striatal nondisplaceable binding potential (BPND)] responses to MP.

127 and, second, to measure the nondisplaceable binding potential (BPND, or the ratio of specific-to-non

128 dings to common coordinates for mouse brain, binding potentials (BPND) and standardized uptake value

129 The binding potentials (BPND) of (11)C-Lu AE92686 in the str

130 PET data were quantified to nondisplaceable binding potentials (BPND) using the Logan graphical anal

131 upply both DAT availability (nondisplaceable binding potential [BPND]) and relative cerebral blood fl

132 g in vivo measures of receptor availability (binding potential, BPND) and DA release (change in BPND

133 atal dopamine D2-type receptor availability (binding potential, BPND) than nonsmokers and exhibit gre

134 Nondisplaceable binding potentials (BPNDs) were calculated using the sim

135 Regional binding potentials (BPNDs) were calculated with the mult

136 Binding potentials (BPnds) were estimated for brain regi

137 Thus, dox and autosomal sites have similar binding potential but are distinguished by linkage to re

138 (11)C-HOMADAM binding potential calculated from the simplified referen

139 de have lower midbrain serotonin transporter binding potential compared with those who do not attempt

140 measured striatal dopamine D2-like receptor binding potential (D2BP) using positron emission tomogra

141 ion of sweetness intensity, and striatal D2R binding potential (D2R BPND) using positron emission tom

142 after amphetamine (change in nondisplaceable binding potential, DeltaBP(ND)) in subregions of the str

143 Percent change in [(11)C]-(+)-PHNO-binding potential (DeltaBPND) was compared between group

144 etamine-induced displacement of [11C]FLB 457 binding potential (DeltaBPND) was significantly smaller

145 ted with a low bias toward identity with the binding potential derived from a reference region (olfac

146 The volume of distribution and binding potential determined with kinetic modeling were

147 clusters and areas of significantly reduced binding potential (determined using Statistical Parametr

148 P = .38), and midbrain serotonin transporter binding potential did not predict future attempts (log-r

149 Parametric images of RAC binding potential during performance of each task were g

150 Binding potential estimates from thirty-five 11C-PBR28 P

151 omycin reflect the importance of noncovalent binding potential, even for covalent inhibitors, in ensu

152 duction of ventral striatum (11)C-raclopride binding potential following reward-related cue exposure,

153 Binding potential for caudate nucleus, putamen, and subs

154 surrogate marker of perfusion to correct the binding potential for impaired radiotracer transfer from

155 Our findings demonstrate that PET-measured binding potentials for CFT and DTBZ for a midbrain volum

156 re used to estimate distribution volumes and binding potentials, for which the cerebellum was used as

157 Voxelwise binding potential ([Formula: see text]) and SUV ratio ([

158 The binding potential images then were spatially normalized,

159 idal intent was not predicted by serotonin1A binding potential in any brain region (F1,10 = 0.83; P =

160 ers had loss of [(11)C]DASB non-displaceable binding potential in brain areas corresponding to Braak

161 ad decreases in [(11)C]DASB non-displaceable binding potential in brain areas corresponding to Braak

162 Modafinil also decreased [(11)C]cocaine binding potential in caudate (53.8% [13.8%]; 95% CI, 43.

163 afinil decreased mean (SD) [(11)C]raclopride binding potential in caudate (6.1% [6.5%]; 95% confidenc

164 ography were used to measure D(2/3) receptor binding potential in cortical regions of interest in rec

165 Similarly, the (18)F-GE180 binding potential in hippocampus was highest to lowest i

166 ps to calculate [(11)C]DASB non-displaceable binding potential in our cohort of A53T SNCA carriers.

167 lacebo, OT significantly reduced [(11)C]DASB binding potential in right amygdala, insula, and hippoca

168 or nearly significant reductions of regional binding potential in subjects with CD in three regions:

169 Decreases in [(11)C]DASB non-displaceable binding potential in the brainstem were associated with

170 By autoradiography, the TSPO radiotracer binding potential in the injected hemisphere was increas

171 : To determine whether serotonin transporter binding potential in the lower midbrain predicts future

172 not attempt suicide, and higher serotonin1A binding potential in the raphe nuclei (RN) is associated

173 controls was reflected by elevated [11C]DASB binding potential in the raphe nuclei region, caudate nu

174 significant reductions in [(11)C]raclopride binding potential in the striatum as a percentage of the

175 [(11)C]DTBZ binding potential in the striatum was derived using the

176 showed loss of [(11)C]DASB non-displaceable binding potential in the ventral (p<0.0001) and dorsal (

177 Using principal-component analysis on the binding potentials in a number of cortical and striatal

178 n serve as a reference region for estimating binding potentials in brain regions.

179 In the NHP experiment, binding potentials in the caudate, putamen, and substant

180 Binding potentials in the striatum and demographic, clin

181 ed binding potential (BPND (non-displaceable binding potential)) in temporal lobes, lateralising acco

182 insula, and hippocampus, whereas [(18)F]MPPF binding potential increased in right amygdala and insula

183 ux rate constant) and a 2.3-fold increase in binding potential (k3/k4) in the 2-tissue-compartment mo

184 Total distribution volume (V(T)) and binding potentials (k3'/k4) of (S)-(-)- and (R)-(+)-(18)

185 onstant kon, dissociation constant koff, and binding potential (kon/koff) in HEK293-hP2X7R cells were

186 e test-retest variability of nondisplaceable binding potential (<10%) and identified the highest nond

187 enil positron emission tomography generating binding potential maps.

188 Binding potential (maximum number of binding sites x aff

189 y of individuals with elevated mean cortical binding potential (MCBP) for PIB rose in an age-dependen

190 ignificant decreases in SERT nondisplaceable binding potential (neocortex, -56%; pallidostriatum, -19

191 orrelation between amygdala response and DRN binding potential (nondisplaceable) (r = -.87, p < .001)

192 Regional estimates of 5-HT1A receptor binding potential (nondisplaceable) were obtained by cal

193 ume (VT), VT normalized by fP (VT/fP), and 3 binding potentials (nondisplaceable binding potential, b

194 erior to (11)C-(R)-PK11195 due to the higher binding potential observed for this ligand.

195 lest bias when compared with nondisplaceable binding potential obtained from LEGA using the metabolit

196 e was the SBR, and the gold standard was the binding potential obtained with wavelet-aided parametric

197 The binding potential of (123)I-ioflupane in the awake state

198 Striatal binding potential of (18)F- AMC20: varied between 0.49 a

199 eys suggested that anesthesia influenced the binding potential of [(11)C]1 and [(11)C]4 at the NET.

200 In agreement with its binding affinity the binding potential of [(18)F]7a (BPND = 5.3-8.0) in contr

201 ls revealed a 3-15-fold increase in relative binding potential of AAV9 particles upon desialylation.

202 strategies that preserve proper folding and binding potential of antibodies by forcing their oriente

203 s) as high-affinity ligands for TTR, but the binding potential of conjugated PCB metabolites such as

204 Based on the calculated basepair-binding potential of each message with the given sRNA re

205 properties and corresponding overall protein-binding potential of individual fragments.

206 TNFalpha regulates the expression and/or DNA-binding potential of key positive-acting and negative-ac

207 The [11C]methylreboxetine-binding potential of NET availability in the locus coeru

208 the GTP-binding domain is important for GTP-binding potential of RBEL1A, because deletion of this re

209 and after maturation to demonstrate a higher binding potential of schizonts compared to other asexual

210 is TF agnostic and likely describes general binding potential of TFs.

211 rmined at 2.4 A revealing an extended ligand binding potential of the antigen groove and a substantia

212 phonate bone imaging, and measurement of the binding potential of the dopamine transporter radioligan

213 ete scaffold-independent analysis of the RNA-binding potential of the four KH domains of KSRP.

214 ratory analyses suggest that the serotonin1A binding potential of the insula (t = 2.41; P = .04), ant

215 The in-depth analysis of the RNA-binding potential of the KH domains of KSRP provides us

216 rticular ligand and that it is the intrinsic binding potential of the protein surface that determines

217 Computational models trained on the binding potential of transcriptional factor (TF) binding

218 PET imaging showed baseline binding potentials of 0.64 +/- 0.07 in the thalamus, 0.5

219 For (11)C-Cimbi-717, nondisplaceable binding potentials of 6.4 +/- 1.2 (n = 6) were calculate

220 was used to estimate quantitative levels of binding potentials of [(11)C](R)-PK11195 in brain region

221 ion in the brain were prepared, and regional binding potentials of NPY2 receptors toward the radiolig

222 The resulting binding potentials of the radioligand declined by 50-60%

223 ceptor availability in vivo (nondisplaceable binding potential, or BP(ND)) was measured with positron

224 This reflected a reduction in portal GLP-1r binding potential, particularly between the splenic vein

225 ecrease in [(11)C]raclopride nondisplaceable binding potential, particularly in the nucleus accumbens

226 These antibodies acquire promiscuous antigen binding potential post-translationally, after exposure t

227 usions and Relevance: Greater RN serotonin1A binding potential predicted higher suicidal ideation and

228 Higher RN serotonin1A binding potential predicted more suicidal ideation at 3

229 e attempts and whether higher RN serotonin1A binding potential predicts future suicidal ideation and

230 Thus, nearly all uptake was specific and the binding potential ranged from 22 in the caudate to 90 in

231 Binding potentials ranging from 2.6 to 4.9 were measured

232 Using a uniform binding potential rather than the water-mediated potenti

233 Parametric maps of [(11)C](R)PK11195 binding potential, rCMRGlc, and [(11)C]PIB uptake were i

234 ed in the corpus callosum, we calculated the binding potential (receptor availability) of the radioli

235 iatal D1- and D2-type receptor availability [binding potential referred to nondisplaceable uptake (BP

236 relative to total plasma concentration, and binding potential relative to free plasma concentration:

237 Parametric images of (11)C-IMA107 binding potential relative to non-displaceable binding (

238 We measured binding potential relative to non-displaceable compartme

239 We determined (11)C-MeNER binding potential relative to nondisplaceable binding po

240 Binding potential relative to nondisplaceable uptake (BP

241 s) and dopamine D2/D3 receptor availability (binding potential relative to nondisplaceable uptake of

242 SUPERPK methodology was used to measure the binding potential relative to the non-specific volume, B

243 [(11)C]-(+)-PHNO BP(ND), the binding potential relative to the nondisplaceable compar

244 ative to nondisplaceable uptake (BP(ND)) and binding potential relative to total plasma concentration

245 tentials (nondisplaceable binding potential, binding potential relative to total plasma concentration

246 Binding potentials relative to non-displaceable binding

247 -(+)-PHNO volumes of distribution (V(T)) and binding potentials relative to the concentration of trac

248 to calculate volume of distribution (VT) and binding potentials relative to the nondisplaceable trace

249 The estimate of target region binding potential (relative to nondisplaceable radioliga

250 s, based on a threshold of the mean cortical binding potential, representing a conversion rate of 3.1

251 A point-mutated HCR/C that lacked GBP2 binding potential retained the ability to bind and enter

252 based on the distribution of [(18)F]AV-1451 binding potential, separated semantic dementia from cont

253 Clusters with significantly reduced binding potential showed virtually no overlap with funct

254 tlas, and percentage injected dose/cm(3) and binding potential (simplified reference tissue model wit

255 [11C]FLB 457 binding potential, specific compared to nondisplaceable

256 ata indicate that lymphostatin has UDP-sugar binding potential that is critical for activity, and is

257 argeting to microvilli is driven by membrane binding potential that is distributed throughout TH1 rat

258 ls caused increases in CBV and reductions in binding potential that were localized to the dopamine-ri

259 Binding potential, the ratio of specifically bound uptak

260 Binding potential, the steady-state ratio of specific bi

261 of a prototypic human antibody that acquires binding potential to glycoprotein (gp) 120 after exposur

262 linking a human protein insert with antigen-binding potential to the constant antibody regions which

263 cified genome for mRNAs that evince basepair-binding potential to the input sRNA sequence.

264 ference to the receptor density expressed in binding potential units.

265 acid decarboxylase), baseline D2/3 receptor-binding potential using [(11)C]raclopride (a weak compet

266 ilability was quantified as non-displaceable binding potential using a kinetic model for reversible l

267 micol to vesicular acetylcholine transporter binding potential value, proportional to vesicular acety

268 ) and identified the highest nondisplaceable binding potential values (from approximately 0.5 in the

269 Binding potential values can be assessed using the pons

270 Regional binding potential values derived from the multilinear an

271 unculopontine nucleus (rho=0.81, P<.004) and binding potential values in both the thalamus (rho=-0.88

272 The range of regional binding potential values in the baboon brain was from 3.

273 In addition, binding potential values in the thalamus were positively

274 control participants, patients with PSP had binding potential values that were unchanged in the stri

275 s and non-infarcted penumbra was mapped, and binding potential values then computed both within and o

276 ltilinear analysis 1-derived nondisplaceable binding potential values were 1.74, 1.79, 1.46, 0.80, an

277 Nondisplaceable binding potential values were calculated using the cereb

278 omise as a PDE2A PET ligand, albeit with low binding potential values.

279 change in [(11)C]raclopride nondisplaceable binding potential was approximately 9%.

280 es 1-3, whereas [(11)C]DASB non-displaceable binding potential was largely preserved in areas corresp

281 cal and pallidostriatal SERT nondisplaceable binding potential was negatively correlated with the num

282 SERT nondisplaceable binding potential was quantified in 12 regions of intere

283 [(11)C]raclopride decrease in binding potential was significantly different from 0 in

284 Binding potential was significantly reduced in the whole

285 concentration in plasma, proportional to the binding potential) was analyzed using multivariate analy

286 nergy potential is calculated to distinguish binding potential wells from which reaction to 1S2R and

287 Images of binding potential were created using the two-step versio

288 Receptor density and binding potential were determined by saturation and asso

289 icant reductions in the [(11)C]P943 regional binding potential were either retained (anterior cingula

290 er SE, increases in (11)C-PK11195 uptake and binding potential were evident in epileptogenesis-associ

291 Levels of 11C-(R)-PK11195 binding potential were measured in a selection of cortic

292 ake value, total volume of distribution, and binding potential were reduced by 38%, 20%, and 40%, res

293 Cerebellar binding potentials were 3.7 for humans, 2.3 for monkeys,

294 cerebellum as the reference region, regional binding potentials were calculated and ranked as follows

295 PK binding potentials were calculated in and around the sit

296 Regional distribution volumes and binding potentials were calculated with 2- and 4-paramet

297 Measured binding potentials were underestimated by 22%-36% when n

298 led to a highly significant reduction in the binding potential, which could be demonstrated using bot

299 nce region for derivation of nondisplaceable binding potential, which ranged from 2.42 in the globus

300 as identified as the ligand with the highest binding potential while still possessing reversible kine